As national drugs regulator’s subject expert committee approves the use of Bharat Biotech’s Covaxin in children between the age-group of 2-18, health experts have welcomed the development saying it will be beneficial for children and help them resume normal lives but added that there is a need to establish its efficacy globally so that the children are not subject to restrictive measures when they travel abroad.